Subcutaneous fast-acting insulin analogues ± long-acting insulin vs IV insulin infusion in DKA: updated meta-analysis of randomised trials.
Diabetic ketoacidosis
Fast-acting insulin analogues
Subcutaneous
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
16 Oct 2024
16 Oct 2024
Historique:
received:
10
08
2024
accepted:
06
10
2024
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
16
10
2024
Statut:
aheadofprint
Résumé
Diabetic ketoacidosis (DKA) is often treated with intravenous regular insulin infusion (IVRII). Subcutaneous fast-acting insulin analogues (FAIAs); either alone or combined with subcutaneous long-acting insulin (LAI); might be useful to treat DKA. Our meta-analysis updated on their benefits and safety in DKA. We searched major electronic databases for randomised trials on subcutaneous FAIAs ± subcutaneous LAI vs IVRII in DKA. Primary outcomes were all-cause in-hospital mortality, time to resolution of DKA and hyperglycemia, in-hospital DKA recurrence and hospital readmission for DKA post-discharge. Secondary outcomes included resource utilisation and patient satisfaction. Safety outcomes were adverse events. Reviewers assessed risk of bias and quality of evidence using GRADE. We performed a priori subgroup and trial sequential analyses on primary outcomes. Seven trials enrolled 351 mainly adult patients (255/351) with mild to moderate DKA. No trials studied subcutaneous FAIA and subcutaneous LAI. Their risk of bias was high or unclear in several domains. No all-cause in-hospital mortality and DKA recurrence were reported. No trial investigated hospital readmission for DKA post-discharge. There was no difference in mean time to resolution of DKA (mean difference = -0.70, 95% CI -2.18 to 0.79 h, p = 0.36) or hyperglycemia [blood glucose < 250 mg/dL (13.9 mmol/L)] (mean difference = -0.17, 95% CI -1.10 to 0.76 h, p = 0.72) between subcutaneous FAIA and IVRII groups. There were largely no subgroup effects. Both groups had similar secondary outcomes. Hypoglycemia was the most common adverse event. Quality of evidence was low to very-low for all outcomes. The only possible trial sequential analysis for time to resolution of DKA was inconclusive. There was low- to very-low quality evidence that subcutaneous FAIA did not affect patient-centered outcomes in mainly adult patients with mild to moderate DKA compared to IVRII.
Sections du résumé
BACKGROUND
BACKGROUND
Diabetic ketoacidosis (DKA) is often treated with intravenous regular insulin infusion (IVRII). Subcutaneous fast-acting insulin analogues (FAIAs); either alone or combined with subcutaneous long-acting insulin (LAI); might be useful to treat DKA. Our meta-analysis updated on their benefits and safety in DKA.
METHODS
METHODS
We searched major electronic databases for randomised trials on subcutaneous FAIAs ± subcutaneous LAI vs IVRII in DKA. Primary outcomes were all-cause in-hospital mortality, time to resolution of DKA and hyperglycemia, in-hospital DKA recurrence and hospital readmission for DKA post-discharge. Secondary outcomes included resource utilisation and patient satisfaction. Safety outcomes were adverse events. Reviewers assessed risk of bias and quality of evidence using GRADE. We performed a priori subgroup and trial sequential analyses on primary outcomes.
RESULTS
RESULTS
Seven trials enrolled 351 mainly adult patients (255/351) with mild to moderate DKA. No trials studied subcutaneous FAIA and subcutaneous LAI. Their risk of bias was high or unclear in several domains. No all-cause in-hospital mortality and DKA recurrence were reported. No trial investigated hospital readmission for DKA post-discharge. There was no difference in mean time to resolution of DKA (mean difference = -0.70, 95% CI -2.18 to 0.79 h, p = 0.36) or hyperglycemia [blood glucose < 250 mg/dL (13.9 mmol/L)] (mean difference = -0.17, 95% CI -1.10 to 0.76 h, p = 0.72) between subcutaneous FAIA and IVRII groups. There were largely no subgroup effects. Both groups had similar secondary outcomes. Hypoglycemia was the most common adverse event. Quality of evidence was low to very-low for all outcomes. The only possible trial sequential analysis for time to resolution of DKA was inconclusive.
CONCLUSIONS
CONCLUSIONS
There was low- to very-low quality evidence that subcutaneous FAIA did not affect patient-centered outcomes in mainly adult patients with mild to moderate DKA compared to IVRII.
Identifiants
pubmed: 39414709
doi: 10.1007/s12020-024-04071-0
pii: 10.1007/s12020-024-04071-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
S. Fazeli Farsani, K. Brodovicz, N. Soleymanlou et al. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open 7, e016587 (2017)
doi: 10.1136/bmjopen-2017-016587
pubmed: 28765134
A.E. Kitabchi, G.E. Umpierrez, J.M. Miles, J.N. Fisher, Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32, 1335–43 (2009)
doi: 10.2337/dc09-9032
pubmed: 19564476
pmcid: 2699725
K.K. Dhatariya, Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults-an updated guideline from the joint British diabetes society for inpatient care. Diabet Med 39, e14788 (2022)
doi: 10.1111/dme.14788
pubmed: 35224769
Y. Handelsman, R.R. Henry, Z.T. Bloomgarden, D. LeRoith, G.E. Umipierrez, M.R. Weir et al. American association of clinical endocrinologists and American College of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 22, 753–62 (2016)
doi: 10.4158/EP161292.PS
pubmed: 27082665
American Diabetes Association Professional Practice Committee, 16. diabetes care in the hospital: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1), S244–53 (2022)
doi: 10.2337/dc22-S016
G. Umpierrez, M. Korytkowski, Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol 12, 222–32 (2016)
doi: 10.1038/nrendo.2016.15
pubmed: 26893262
A. Modi, A. Agrawal, F. Morgan, Euglycemic diabetic ketoacidosis: A review. Curr Diabetes Rev 13, 315–21 (2017)
doi: 10.2174/1573399812666160421121307
pubmed: 27097605
L. Barski, T. Eshkoli, E. Brandstaetter, A. Jotkowitz, Euglycemic diabetic ketoacidosis. Eur J Intern Med 63, 9–14 (2019)
doi: 10.1016/j.ejim.2019.03.014
pubmed: 30910328
C. Hurlock-Chorostecki, Managing diabetic ketoacidosis: the role of the ICU nurse in an endocrine emergency. Dynamics 15, 18–22 (2004)
pubmed: 15460517
J.L. Kelly, Continuous insulin infusion: when, where, and how? Diabetes Spectr 27, 218–23 (2014)
doi: 10.2337/diaspect.27.3.218
pubmed: 26246783
pmcid: 4523736
T Donner, S Sarkar, Insulin – pharmacology, therapeutic regimens, and principles of intensive insulin therapy. South Dartmouth (MA): MDText.com, Inc.
C.A. Andrade-Castellanos, L.E. Colunga-Lozano, N. Delgado-Figueroa, D.A. Gonzalez-Padilla, Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev 2016, CD011281 (2016)
pubmed: 26798030
pmcid: 8829395
Z. Razavi, S. Maher, J. Friedman, Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. Endocrine 81, 267–74 (2018).
L. Cardoso, N. Vicente, D. Rodrigues, L. Gomes, F. Carrilho, Controversies in the management of hyperglycaemic emergencies in adults with diabetes. Metabolism 68, 43–54 (2017)
doi: 10.1016/j.metabol.2016.11.010
pubmed: 28183452
P. Rao, S.-F. Jiang, P. Kipnis, D.M. Patel, S. Katsnelson, S. Madani et al. Evaluation of outcomes following hospital-wide implementation of a subcutaneous insulin protocol for diabetic ketoacidosis. JAMA Netw Open 5, e226417 (2022)
doi: 10.1001/jamanetworkopen.2022.6417
pubmed: 35389497
pmcid: 8990349
T.V. Pereira, J.P.A. Ioannidis, Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. J Clin Epidemiol 64, 1060–9 (2011)
doi: 10.1016/j.jclinepi.2010.12.012
pubmed: 21454050
A. Afshari, J. Wetterslev, A.F. Smith, Can systematic reviews with sparse data be trusted? Anaesthesia 72, 12–6 (2017)
doi: 10.1111/anae.13730
pubmed: 27804113
J. Wetterslev, J.C. Jakobsen, C. Gluud, Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 17, 39 (2017)
doi: 10.1186/s12874-017-0315-7
pubmed: 28264661
pmcid: 5397700
A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P.A. Loannidis et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ 339, b2700 (2009)
doi: 10.1136/bmj.b2700
pubmed: 19622552
pmcid: 2714672
B.L. Lim, W.F. Lee, B. Lee, Y.E. Lynette Chung, K.V. Loo, Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials. BMJ Open 13, e070131 (2023). https://doi.org/10.1136/bmjopen-2022-070131
doi: 10.1136/bmjopen-2022-070131
pubmed: 36764729
pmcid: 9923333
E Karslioglu E French, AC Donihi, MT Korytkowski, Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. BMJ 2019:l1114
Cochrane Effective Practice and Organisation of Care (EPOC). Data collection form. EPOC resources for review authors. 2021. Available: epoc.cochrane.org/resources/epoc-specific-resources-review-authors [Accessed 19 Sep 2022]
J.P.T. Higgins, D.G. Altman, P.C. Gøtzsche, P. Jüni, D. Moher, A.D. Oxman et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011)
doi: 10.1136/bmj.d5928
pubmed: 22008217
pmcid: 3196245
G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924–6 (2008)
doi: 10.1136/bmj.39489.470347.AD
pubmed: 18436948
pmcid: 2335261
X. Wan, W.Q. Wang, J.M. Liu, T.J. Tong, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14, 135 (2014)
doi: 10.1186/1471-2288-14-135
pubmed: 25524443
pmcid: 4383202
S.P. Hozo, B. Djulbegovic, I. Hozo, Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5, 13 (2005)
doi: 10.1186/1471-2288-5-13
pubmed: 15840177
pmcid: 1097734
M. Bland, Estimating mean and standard deviation from the sample size, three quartiles, minimum, and maximum. Int J Stats in Med Res 4, 57–64 (2015)
doi: 10.6000/1929-6029.2015.04.01.6
J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman, Measuring inconsistency in meta-analyses. BMJ 327, 557–60 (2003)
doi: 10.1136/bmj.327.7414.557
pubmed: 12958120
pmcid: 192859
D.G. Altman, J.M. Bland, Interaction revisited: the difference between two estimates. BMJ 326, 219 (2003)
doi: 10.1136/bmj.326.7382.219
pubmed: 12543843
pmcid: 1125071
G.E. Umpierrez, R. Cuervo, A. Karabell, K. Latif, A.X. Freire, A.E. Kitabchi, Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 27, 1873–8 (2004)
doi: 10.2337/diacare.27.8.1873
pubmed: 15277410
G.E. Umpierrez, K. Latif, J. Stoever, R. Cuervo, L. Park, A.X. Freire et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med 117, 291–6 (2004)
doi: 10.1016/j.amjmed.2004.05.010
pubmed: 15336577
T. Della Manna, L. Steinmetz, P.R. Campos, S.C. Farhat, C. Schvartsman, H. Kuperman et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 28, 1856–61 (2005)
doi: 10.2337/diacare.28.8.1856
pubmed: 16043723
H.O. Ersöz, K. Ukinc, M. Köse, C. Erem, A. Gunduz, A.B. Hacihasanoglu et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int J Clin Pract 60, 429–33 (2006)
doi: 10.1111/j.1368-5031.2006.00786.x
pubmed: 16620355
R. Karoli, J. Fatima, T. Salman, S. Sandhu, R. Shankar, Managing diabetic ketoacidosis in non-intensive care unit setting: Role of insulin analogs. Indian J Pharmacol 43, 398–401 (2011)
doi: 10.4103/0253-7613.83109
pubmed: 21844993
pmcid: 3153701
I. Ahmed, S. Sabir Ali, Z. Ali, N. Mohammad, T. Ghaffar, Management of diabetic ketoacidosis: role of rapid acting insulin analogs in comparison to regular intravenous insulin. Int J Endorsing Health Sci Res 9, 76–82 (2021). 2021
doi: 10.29052/IJEHSR.v9.i1.2021.76-82
D. Desai, D. Mehta, P. Mathias, G. Menon, U.K. Schubart, Health care utilization and burden of diabetic ketoacidosis in the US over the past decade: a nationwide analysis. Diabetes Care 41, 1631–8 (2018)
doi: 10.2337/dc17-1379
pubmed: 29773640
S.R. Benoit, Y. Zhang, L.S. Geiss, E.W. Gregg, A. Albright, Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality - United States, 2000-2014. MMWR Morb Mortal Wkly Rep 67, 362–5 (2018)
doi: 10.15585/mmwr.mm6712a3
pubmed: 29596400
pmcid: 5877353
N.D. Karajgikar, P. Manroa, R. Acharya, R.A. Codario, J.A. Reider et al. Addressing pitfalls in management of diabetic ketoacidosis with a standardized protocol. Endocr Pract 25, 407–12 (2019)
doi: 10.4158/EP-2018-0398
pubmed: 30657360
L. Chow, W. Valesky, Subcutaneous rapid-acting insulin analogs for diabetic ketoacidosis. Acad Emerg Med 28, 700–2 (2021)
doi: 10.1111/acem.14170
pubmed: 33145848